PTEN INACTIVATION AND ALTERATION OF THE PI3K/AKT/mTOR PATHWAY IN BILIARY TRACT CANCER

被引：0
|
作者：
Petzold, J. [1 ]
Lederer, E. [1 ]
Reihs, R. [1 ]
Ernst, C. [1 ]
Bettermann, K. [1 ]
Halbwedl, I. [1 ]
Lax, S. [2 ]
Park, Y. N. [3 ]
Kim, K. S. [4 ]
Kiesslich, T. [5 ]
Pichler, M. [6 ]
Obrist, P. [7 ]
Haybaeck, J. [1 ]
机构：
[1] Med Univ Graz, Inst Pathol, Graz, Austria
[2] Hosp Graz West, Dept Pathol, Graz, Austria
[3] Yonsei Univ, Coll Med, Dept Pathol, Project Med Sci BK21PLUS, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[5] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Salzburg, Austria
[6] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[7] Inst Pathol, Zams, Austria
来源：
ANTICANCER RESEARCH | 2014年 / 34卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
244
引用
收藏
页码：5942 / 5943
页数：2
相关论文
共 50 条
  • [41] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [42] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [43] Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
    Ching, Christina Barbara
    Hansel, Donna Elizabeth
    LABORATORY INVESTIGATION, 2010, 90 (10) : 1406 - 1414
  • [44] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Antonino Glaviano
    Aaron S. C. Foo
    Hiu Y. Lam
    Kenneth C. H. Yap
    William Jacot
    Robert H. Jones
    Huiyan Eng
    Madhumathy G. Nair
    Pooyan Makvandi
    Birgit Geoerger
    Matthew H. Kulke
    Richard D. Baird
    Jyothi S. Prabhu
    Daniela Carbone
    Camilla Pecoraro
    Daniel B. L. Teh
    Gautam Sethi
    Vincenzo Cavalieri
    Kevin H. Lin
    Nathalie R. Javidi-Sharifi
    Eneda Toska
    Matthew S. Davids
    Jennifer R. Brown
    Patrizia Diana
    Justin Stebbing
    David A. Fruman
    Alan P. Kumar
    Molecular Cancer, 22
  • [45] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
    Wu, P.
    Hu, Y-Z
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
  • [46] The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
    Cheaib, Bianca
    Auguste, Aurelie
    Leary, Alexandra
    CHINESE JOURNAL OF CANCER, 2015, 34 (01) : 4 - 16
  • [47] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285
  • [48] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [49] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    HaiXia Li
    JianFang Zeng
    Keng Shen
    Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
  • [50] Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer
    Alves, Carla L.
    Ditzel, Henrik J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
12345